Improvements in Lung Function with Nebulized Revefenacin in the Treatment of Patients with Moderate to Very Severe COPD: Results from Two Replicate Phase III Clinical Trials

Background: Revefenacin, a novel, lung-selective, long-acting muscarinic antagonist, has been developed for nebulized therapy for chronic obstructive pulmonary disease (COPD). We present the results of replicate Phase III efficacy and safety studies of revefenacin in patients with moderate to very s...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Chronic Obstr Pulm Dis
Hauptverfasser: Ferguson, Gary T., Feldman, Gregory, Pudi, Krishna K., Barnes, Chris N., Moran, Edmund J., Haumann, Brett, Pendyala, Srikanth, Crater, Glenn
Format: Artigo
Sprache:Inglês
Veröffentlicht: COPD Foundation Inc 2019
Schlagworte:
Original Research
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6596436/
https://ncbi.nlm.nih.gov/pubmed/30974049
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.15326/jcopdf.6.2.2018.0152
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge